Clinical trials: Leptospirosis
Malaria Fever, Zika
Xpert® Tropical Fever Test on GeneXpert® Edge X System
This is a multi-site, observational, cross-sectional clinical study that includes geographically diverse sites within and outside the United States.
- Conditions
- Malaria Fever, Zika, Dengue Fever, Leptospirosis
- Trial name
- NCT07520279
- Testing
- Xpert Tropical Fever test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Cepheid
Leptospirosis, Jarisch Herxheimer Reaction
Ex Vivo Study of Leukocyte Responses in the Blood of Patients With Leptospirosis and ex Vivo Testing of a New Host-targeted Therapeutic Strategy to Restore Phagocytosis of Leptospira
Leptospirosis is a neglected zoonosis caused by pathogenic spirochetes of the genus *Leptospira*, occurring mainly in humid tropical and subtropical regions.
- Trial name
- NEUTROLEPTO-NC (NCT07611591)
- Testing
- 24 ml blood sample at H0, 16 ml blood sample at H3
- Volunteers
- 70 people
- Sponsor
- Institut Pasteur
Leptospirosis
Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI
Leptospirosis is a zoonosis found worldwide, but particularly in humid subtropical and tropical zones. It is caused by pathogenic bacteria of the Leptospira species of the spirochete family.
- Trial name
- NIHFI (NCT06945822)
- Testing
- Blood sample, Urine Sample
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Leptospirosis, Jarisch Herxheimer Reaction
Study of the Incidence of Jarisch-Herxheimer Reaction in Leptospirosis Patients in New Caledonia
The objective of the study is to estimate the incidence of Jarisch-Herxheimer Reactions (JHR) during antibiotic treatment of human leptospirosis cases in New Caledonia.
- Trial name
- LEPJARNC (NCT04882046)
- Testing
- Blood collection, Data collection
- Where
- 5 sites in New Caledonia
- Volunteers
- 900 people
- Sponsor
- Institut Pasteur
Leptospirosis
Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine
The study aims to assess antibody persistence induced by Spirolept® vaccination in subjects who received at least 4 doses (2 doses two weeks apart and 2 booster doses) and no more than a total of 8 doses (2 doses two weeks apart…
- Trial name
- SPT-001 (NCT03497572)
- Where
- 2 sites in France
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Imaxio